What is Colinz Laboratories Ltd (531210) share price return in the past 10 years?

Colinz Laboratories Ltd share price has appreciated 17.2% annually (CAGR) over the past ten years.

What is the share price of Colinz Laboratories Ltd (531210)?

Company share prices are keep on changing according to the market conditions. The current trading price of Colinz Laboratories Ltd (531210) on 04-Jun-2026 16:59:59 at 16:59 is 58.84.

What is the P/E ratio of Colinz Laboratories?

The latest standalone P/E ratio of Colinz Laboratories as of 04-Jun-2026 is 28.89.

What is the P/B ratio of Colinz Laboratories Ltd (531210)?

The latest standalone P/B ratio of Colinz Laboratories Ltd (531210) as of 04-Jun-2026 is 1.48.

What is the 52-week high and low of Colinz Laboratories Ltd (531210)?

The 52-week high of Colinz Laboratories Ltd (531210) is Rs. 87.91 and the 52-week low is Rs. 36.11.

Colinz Laboratories Ltd (531210) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Colinz Laboratories Ltd (531210)
Brand: Colinz Laboratories

Colinz Laboratories Ltd (531210)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531210 NSE: Pharmaceuticals & Drugs | Small Cap | Colinz Laboratories Share Price

Colinz Laboratories Ltd (531210)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531210 NSE: Pharmaceuticals & Drugs | Small Cap | Colinz Laboratories Share Price

Key Metrics

Valuation Multiples

Market Cap

₹15 Cr.

Current Price

₹58.8

52-Week Low / High

₹36 / 88

TTM EPS

₹2

TTM Sales

₹6.1 Cr.

Book Value per Share

₹39.9

P/E Ratio

28.89

Higher than its 5-year historical median

Industry PE

46.5

Price to Book (P/B)

1.48

Higher than its 5-year historical median

Price to Sales (P/S)

2.42

Higher than its 5-year historical median

EV/EBITDA

7.50

In line with its 5-year historical median

Dividend Yield

0.00%

Profitability Efficiency

Return on Equity (ROE)

5.39%

Underperforms industry median

Return on Capital Employed (ROCE)

6.74%

Underperforms industry median

Return on Assets (ROA)

4.29%

Operating Profit Margin

7.6%

Net Profit Margin

7.61%

Gross Profit Margin

11.5%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

-7.11%

Operating Profit Growth (1 Year)

Slowing versus 3-year growth rate

-7.41%

Net Profit Growth (1 Year)

Slowing versus 3-year growth rate

2.04%

Asset Quality

Promoter Holding

66.00%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹8 Cr.

Equity

₹2.5 Cr.

Face Value

₹10

All Time Low / High

₹0.25 / 88.70

Colinz Laboratories stock performance

Key Ratios

Check Before You Invest

M-Cap below 100cr DeciZen not available

Q.1 Is Colinz Laboratories Ltd a good quality company?

Colinz Laboratories Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Colinz Laboratories Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Colinz Laboratories Ltd vs industry peers?

Colinz Laboratories Ltd revenue CAGR is -2.84%, compared to the industry median CAGR of 5.35%, indicating slower growth and losing its market share.

Q.1 Promoter shareholding and pledge status of Colinz Laboratories Ltd?

Promoters hold 66.00% of the Colinz Laboratories Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Colinz Laboratories Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 12.9% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	3.3%	3.1%	3.3%	3.5%	3.3%	4.3%	6.8%	7.9%	7.7%	6.7%	-
Value Creation Index ⓘ	-0.8	-0.8	-0.8	-0.8	-0.8	-0.7	-0.5	-0.4	-0.5	-0.5	-
Growth Parameters ⓘ
Sales ⓘ	8.1	8.1	7.9	7.6	7.5	6.1	7	7.2	7	6.5	6
Sales YoY Gr.	-	-0.6%	-1.9%	-4.1%	-0.5%	-19%	13.8%	2.9%	-1.7%	-7.1%	-
Adj EPS ⓘ	0.3	0.4	0.7	0.3	0.4	0.5	0.7	1.9	1.9	2	2
YoY Gr.	-	48.2%	62.5%	-47.7%	8.8%	21.6%	64.4%	154.1%	2.7%	1%	-
BVPS (₹) ⓘ	17.7	18.4	19.1	19.3	19.3	20.6	21.7	32.3	35.5	37.6	39.9
Adj Net Profit ⓘ	0.1	0.1	0.2	0.1	0.1	0.2	0.3	0.5	0.5	0.5	1
Cash Flow from Ops. ⓘ	0.6	0.1	0.3	0.1	0.6	2.2	0.5	0.4	1	-1.5	-
Debt/CF from Ops. ⓘ	2.8	13.3	1.3	5.8	0.7	0.5	1	0.7	0.6	-0.4	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-2.4%	-2.8%	-2.1%	-7.1%
Adj EPS ⓘ	24.6%	39.4%	38.1%	1%
BVPSⓘ	8.8%	14.3%	20.1%	5.9%
Share Price	17.2%	31.9%	15.6%	-6%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	1.5	2.2	3.5	1.8	1.9	2.9	4.5	6	5.7	5.3	5.3
Op. Profit Mgn % ⓘ	5.6	5.1	4.5	4.6	4	5.4	8.4	8.8	7.7	7.6	6.6
Net Profit Mgn % ⓘ	1.2	1.8	2.9	1.6	1.7	3.4	4.9	6.6	6.9	7.5	8.4
Debt to Equity ⓘ	0.3	0.1	0.1	0.1	0.1	0.1	0.1	0	0.1	0.1	0
Working Cap Days ⓘ	226	226	224	220	198	195	130	110	101	148	279
Cash Conv. Cycle ⓘ	122	136	137	145	143	135	89	73	59	50	213

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	8.10	8.05	7.90	7.58	7.54	6.11	6.95	7.15	7.03	6.53
Operating Expenses ⓘ +	7.64	7.64	7.54	7.23	7.23	5.78	6.36	6.55	6.49	6.03
Manufacturing Costs	0.20	0.20	0.35	0.16	0.15	0.20	0.18	0.19	0.19	0.19
Material Costs	3.48	2.94	2.73	2.80	2.74	2.18	2.30	2.29	2.31	2.09
Employee Cost	2.86	2.91	3.15	3.07	3.25	2.39	2.77	2.90	2.79	2.67
Other Costs ⓘ	1.09	1.58	1.31	1.20	1.08	1	1.11	1.17	1.19	1.08
Operating Profit ⓘ	0.45	0.41	0.36	0.35	0.30	0.33	0.59	0.61	0.54	0.50
Operating Profit Margin (%)	5.6%	5.1%	4.5%	4.6%	4.0%	5.4%	8.4%	8.5%	7.7%	7.6%
Other Income ⓘ +	0.10	0.09	0.10	0.12	0.13	0.19	0.17	0.17	0.28	0.30
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	0.12	0.12	0.08	0.10	0.07	0.09	0.08	0.05	0.04	0.04
Depreciation ⓘ	0.28	0.27	0.22	0.22	0.19	0.19	0.20	0.13	0.13	0.13
Profit Before Tax ⓘ	0.15	0.12	0.15	0.16	0.18	0.25	0.48	0.60	0.65	0.62
Tax ⓘ	0.06	-0.02	-0.08	0.03	0.05	0.04	0.14	0.14	0.16	0.12
Profit After Tax	0.09	0.14	0.23	0.12	0.13	0.21	0.34	0.46	0.49	0.50
PAT Margin (%)	1.2%	1.8%	2.9%	1.6%	1.7%	3.4%	4.9%	6.4%	6.9%	7.6%
Adjusted EPS (₹)	0.3	0.4	0.7	0.3	0.4	0.6	1.0	1.8	1.9	2.0
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Valuation of Colinz Laboratories - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	6.26	6.52	6.75	6.84	6.84	7.29	7.69	8.14	8.95	9.47
Share Capital ⓘ	3.54	3.54	3.54	3.54	3.54	3.55	3.55	2.52	2.52	2.52
Reserves ⓘ	2.71	2.98	3.21	3.30	3.29	3.75	4.14	5.62	6.43	6.96
Debt +	1.60	0.76	0.42	0.68	0.38	0.99	0.48	0.27	0.57	0.64
Long Term Debt	1.60	0	0	0	0	0	0	0	0	0
Short Term Debt	0	0.76	0.42	0.68	0.38	0.99	0.48	0.27	0.57	0.64
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	0.58	0.45	0.68	0.34	0.37	0.54	0.48	0.65	0.60	0.54
Others Liabilities ⓘ	1.32	1.94	1.74	1.31	1.22	1.27	1.28	1.16	1.24	1.16
Total Liabilities ⓘ	9.75	9.67	9.59	9.17	8.81	10.10	9.93	10.23	11.36	11.82
Fixed Assets
Net Fixed Assets ⓘ +	2.88	2.63	2.41	2.21	2.06	2.03	1.86	1.71	1.58	1.70
Gross Block	6.64	6.66	6.66	6.67	6.72	6.88	6.91	6.17	6.17	6.43
Accumulated Depreciation	3.76	4.03	4.25	4.46	4.66	4.85	5.05	4.46	4.60	4.73
CWIP ⓘ	0	0	0	0	0	0	0	0	0	0
Investments ⓘ	0.29	0.41	0.53	0.50	0.36	0.61	0.67	0.66	1.02	1.04
Inventories	2.22	2.16	1.97	1.90	1.69	1.25	0.93	0.94	0.85	0.78
Trade Receivables	1.35	1.47	1.68	1.68	1.49	1.30	1.21	1.13	0.86	0.66
Cash Equivalents ⓘ	1.62	1.63	1.87	1.99	2.60	4.68	5.21	5.73	7	5.55
Others Assets ⓘ	1.40	1.37	1.13	0.90	0.61	0.25	0.06	0.06	0.05	2.08
Total Assets ⓘ	9.75	9.67	9.59	9.17	8.81	10.10	9.93	10.23	11.36	11.82

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	0.58	0.06	0.34	0.12	0.58	2.16	0.47	0.40	1.03	-1.45
PBT ⓘ	0.15	0.12	0.15	0.16	0.18	0.25	0.48	0.60	0.65	0.62
Adjustment ⓘ	0.28	0.29	0.21	0.19	0.13	0.11	0.11	0.03	-0.11	-0.12
Changes in Working Capital ⓘ	0.17	-0.33	0.01	-0.21	0.34	1.88	0.03	-0.07	0.67	-1.75
Tax Paid ⓘ	-0.03	-0.03	-0.03	-0.03	-0.07	-0.08	-0.15	-0.16	-0.18	-0.21
Cash Flow From Investing Activity ⓘ +	-0	-0.01	-0.11	-0.01	-0.04	-0.15	-0.03	0.01	0.01	-0.23
Capex	-0	-0.02	0	0	-0.04	-0.16	-0.04	0	0	-0.26
Net Investments	0	0	-0.11	-0.01	0	0	0	0	0	0.02
Others ⓘ	0	0	0	0	0.01	0	0.01	0.01	0.01	0.01
Cash Flow From Financing Activity ⓘ +	-0.73	-0.03	0.01	0.02	0.06	0.08	0.09	0.11	0.23	0.24
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	-0.73	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	-0.03	-0.08	-0.10	-0.07	-0.09	-0.08	-0.05	-0.04	-0.04
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	0	0.09	0.12	0.13	0.17	0.17	0.16	0.27	0.28
Net Cash Flow ⓘ	-0.16	0.02	0.24	0.12	0.60	2.08	0.52	0.52	1.27	-1.45

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	1.52	2.21	3.48	1.79	1.91	2.94	4.53	5.78	5.7	5.39
ROCE (%)	3.27	3.12	3.25	3.45	3.3	4.28	6.76	7.86	7.67	6.74
Asset Turnover Ratio	0.82	0.83	0.83	0.82	0.85	0.65	0.7	0.71	0.65	0.56
PAT to CFO Conversion(x)	6.44	0.43	1.48	1	4.46	10.29	1.38	0.87	2.1	-2.9
Working Capital Days
Receivable Days	58.70	63.80	72.20	80	76.10	82.60	65.50	59.70	51.80	42.50
Inventory Days	105.90	99.30	94.70	92	86.20	87.10	56.80	47.60	46.40	45.50
Payable Days	86.10	63.70	75.30	66.30	47.40	76.30	80.90	89.90	98.80	99.60

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Colinz Laboratories Ltd FAQs

The current trading price of Colinz Laboratories on 04-Jun-2026 16:59 is ₹58.84.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Jun-2026 the market cap of Colinz Laboratories stood at ₹14.82 Cr

The latest P/E ratio of Colinz Laboratories as of 03-Jun-2026 is 28.89.

The latest P/B ratio of Colinz Laboratories as of 03-Jun-2026 is 1.48.

The 52-week high of Colinz Laboratories is ₹87.91 and the 52-week low is ₹36.11.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Colinz Laboratories is ₹6.14 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Colinz Laboratories Ltd is a average quality company.

The key valuation ratios of Colinz Laboratories Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Colinz Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Colinz Laboratories Ltd

Colinz Laboratories was established in 1987, the company is having modern manufacturing facility near Mumbai. The company is equipped with a full fledged in house testing / quality control laboratory.

The company houses well experienced pharmacists / technical personnel in development dept / manufacturing and caters to an ethical promotion of specialty products in India.

The company is having a well experienced marketing team of over 300 personnels and is having expertise in turn key projects (Design, erection & commissioning of pharma formulation plants) Transfer of technical know how (Pilot Batch to Commercial productions).

Business area of the company spreads to:

Pharmaceutical Formulations (of all dosages forms)

Tablets
Capsules
Parenterals
Creams/ Ointments/Lotions
Dry Powder
Liquid Orals
Soft Gelatine Capsules

Therapeutic Segments

Anti Biotics & Anti Bacterials
Anti Hypertensives
Diuretics
Lipid lowering Agents (Cholestrole Reducers)
Anti Emetics etc.

Vetinary formulations

Feed mix
Bolus
Vitamins & Others

Nutraceuticals

Spirulina
Co enzyme Q10
Clucosamine
Lecithin
Vitamins

Herbal Preparations

Pain Balm (Instant relief for all types of pain)
Anti Cold Rub

Ayurvedic Skin Care Creams Treatment of

Pimples
Fairness
Stretch Marks
Cracks

Capsules/Tablets/ Creams/ Powders

Anti Piles
Laxatives
Anti Diabetic
Anti Hypertensive
Antacid
Vigour & Vitality
General Debility

Contract Manufacturing & Technical Know How Product Development

- Product Development & Clinical Research - Technical know how for formulations - Currently Manufacturing for Europeon & Japanese companies

Sourcing API& / Intermediates Turn key products

Colinz Laboratories Ltd (531210)

Colinz Laboratories Ltd (531210)

Colinz Laboratories stock performance